GlassScriptPhysician profile
Mark Steven Owens
NPI 1922218015
$285,670.97
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143K · 2020: $20K · 2021: $26K · 2022: $49K · 2023: $43K · 2024: $4,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $8,416 · Consulting Fee: $8,220 · Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,635.00 |
| Travel and Lodging | $8,415.56 |
| Consulting Fee | $8,220.00 |
| Food and Beverage | $1,251.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $97,283.57 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84,091.29 | 2020-2023 | |
| Ironshore Pharmaceuticals INC. | $48,914.10 | 2019-2023 | Jornay Pm |
| Corium, LLC | $17,528.40 | 2023-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $12,240.39 | 2019-2022 | |
| Adlon Therapeutics L.P. | $9,541.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,094.76 | 2019-2021 | |
| Tris Pharma INC | $4,748.45 | 2019 | |
| Shire North American Group INC | $3,205.15 | 2019 | |
| Neos Therapeutics, LP | $23.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.